Martin Shkreli Was Just Convicted on 3 Counts of Securities Fraud

"Pharma bro" Martin Shkreli was found guilty on three of eight counts of securities fraud.
Updated
Stocks quotes in this article: RTRX

After five days of deliberation, a Brooklyn jury found Martin Shkreli, the former CEO of the biotech firm Retrophin (RTRX) as well as the founder of Turing Pharmaceuticals AG, guilty on three of eight counts of securities fraud. 

Read More: Pharma Bro Martin Shkreli 'Delighted' With Verdict in Fraud Case

Watch More with TheStreet:

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

TAGS: Investing | Video | Hedge Funds | Biotechnology | Natural Gas | Economy | Media | Gaming | Consumer Services | Technology | Economic Data | Regulation | Healthcare | Financial Services |

More from Video

Amid the Selling, Here's the Big Question Now

James "Rev Shark" DePorre

How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.

One Tweet Pulls the Rug Out From Under the Indexes

James "Rev Shark" DePorre

Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.

A Technical Look at the New Dow Jones Industrial Average

Bruce Kamich

Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.

Conagra Brands Looks Tastier After Its Upgrade to Buy

Bruce Kamich

CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Bruce Kamich

Breaking down an approach to the long side of this biotech stock.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight